OBJECTIVE: To conduct a study to determine whether diabetes treatment is associated with benign prostatic hyperplasia (BPH)/lower urinary tract symptoms (LUTS) and progression in black and white men. Diabetes has been associated with BPH and LUTS in aging men. METHODS: Using the Olmsted County Study of Urinary Symptoms and Health Status among Men and the Flint Men's Health Study, we examined how the use of medical therapy (eg, insulin regimens, oral hypoglycemics) related to changes in LUTS severity, maximal urinary flow rate measured by uroflowmetry, prostate volume determined by transrectal ultrasonography, and serum prostate-specific antigen concentrations. RESULTS: Of the 2226 men participating in the Olmsted County Study of Urinary Symptoms and Health Status among Men and the Flint Men's Health Study, 186 men reported a history of diabetes, 76.9% of whom were treated with medical therapy. Overall, the men with diabetes had significantly greater odds of moderate/severe LUTS (age- and race-adjusted odds ratio 1.37, 95% confidence interval 1.00-1.87) compared with those without diabetes. However, among the diabetic men, those not taking medication had greater odds of moderate/severe LUTS than those taking medication. This association among men not taking medication was seen for 5 of the 7 individual symptoms. The prostate volume and prostate-specific antigen level were not significantly associated with diabetes treatment. No significant differences were observed for the annual change in BPH characteristics by diabetes treatment status. CONCLUSION: These findings suggest that the presence of diabetes and subsequent poor glycemic control might be less related to prostate growth and more to the dynamic components of lower urinary tract function. Additional evaluations of the associations between glycemic control and BPH progression are warranted.
OBJECTIVE: To conduct a study to determine whether diabetes treatment is associated with benign prostatic hyperplasia (BPH)/lower urinary tract symptoms (LUTS) and progression in black and whitemen. Diabetes has been associated with BPH and LUTS in aging men. METHODS: Using the Olmsted County Study of Urinary Symptoms and Health Status among Men and the Flint Men's Health Study, we examined how the use of medical therapy (eg, insulin regimens, oral hypoglycemics) related to changes in LUTS severity, maximal urinary flow rate measured by uroflowmetry, prostate volume determined by transrectal ultrasonography, and serum prostate-specific antigen concentrations. RESULTS: Of the 2226 men participating in the Olmsted County Study of Urinary Symptoms and Health Status among Men and the Flint Men's Health Study, 186 men reported a history of diabetes, 76.9% of whom were treated with medical therapy. Overall, the men with diabetes had significantly greater odds of moderate/severe LUTS (age- and race-adjusted odds ratio 1.37, 95% confidence interval 1.00-1.87) compared with those without diabetes. However, among the diabeticmen, those not taking medication had greater odds of moderate/severe LUTS than those taking medication. This association among men not taking medication was seen for 5 of the 7 individual symptoms. The prostate volume and prostate-specific antigen level were not significantly associated with diabetes treatment. No significant differences were observed for the annual change in BPH characteristics by diabetes treatment status. CONCLUSION: These findings suggest that the presence of diabetes and subsequent poor glycemic control might be less related to prostate growth and more to the dynamic components of lower urinary tract function. Additional evaluations of the associations between glycemic control and BPH progression are warranted.
Authors: Aruna V Sarma; Craig A Jaffe; David Schottenfeld; Rodney Dunn; James E Montie; Kathleen A Cooney; John T Wei Journal: Urology Date: 2002-03 Impact factor: 2.649
Authors: Rosebud O Roberts; Michael M Lieber; Debra J Jacobson; Cynthia J Girman; Steven J Jacobsen Journal: Mayo Clin Proc Date: 2005-06 Impact factor: 7.616
Authors: Varant Kupelian; Kevin T McVary; Steven A Kaplan; Susan A Hall; Carol L Link; Lalitha Padmanabhan Aiyer; Patrick Mollon; Nihad Tamimi; Raymond C Rosen; John B McKinlay Journal: J Urol Date: 2009-06-18 Impact factor: 7.450
Authors: Peter Weibl; Tobias Klatte; Peter Laurinc; Roman Tomaškin; Shahrokh F Shariat; Miroslav Helbich; Danica Fackovcova; Peter Bujdák Journal: Wien Klin Wochenschr Date: 2014-12-02 Impact factor: 1.704
Authors: Lauren P Wallner; John M Hollingsworth; Rodney L Dunn; Catherine Kim; William H Herman; Aruna V Sarma Journal: Urology Date: 2013-07-31 Impact factor: 2.649
Authors: Stephen K Van Den Eeden; Assiamira Ferrara; Jun Shan; Steven J Jacobsen; Virginia P Quinn; Reina Haque; Charles P Quesenberry Journal: BMC Urol Date: 2013-02-20 Impact factor: 2.264
Authors: W Tristram Arscott; Leonard N Chen; Nathan Wilson; Aditi Bhagat; Joy S Kim; Rudy A Moures; Thomas M Yung; Siyuan Lei; Brian T Collins; Keith Kowalczyk; Simeng Suy; Anatoly Dritschilo; John H Lynch; Sean P Collins Journal: Radiat Oncol Date: 2014-07-24 Impact factor: 3.481